Preparing for Disease X
Tuesday, November 8th 2022
Welcome to mRNA Access
At Moderna, we are grounded in the belief that mRNA is transformational. And, for us, our COVID-19 vaccine Spikevax® is just the beginning.
Our mRNA platform, with its speed, scale, and flexibility, is uniquely suited to tackle current and emerging pathogens that threaten global health.
mRNA Access, powered by Moderna, invites you to be part of what comes next.
mRNA Access aims to accelerate the creation of new vaccines using mRNA technology in collaboration with global partners.
Through the program, researchers beyond Moderna can take advantage of the flexibility afforded by our platform to develop novel mRNA medicines for emerging and neglected infectious diseases.
At Moderna, we understand that the COVID-19 pandemic will not be our last. And our mission is to support scientists around the world as they work to protect our global health.
What we provide
mRNA Access invites you to partner with us to explore the possibility of mRNA for the benefit of global health.
Moderna has spent a decade developing our mRNA platform to advance mRNA medicines. Our iterative vaccine design approach to emerging infectious disease like SARS-CoV-1 and MERS enabled our COVID-19 vaccine and allowed us to realize the potential of our platform to positively impact the lives of hundreds of millions of people.
Through mRNA Access, we invite researchers around the world to design novel vaccines against emerging and neglected infectious diseases, and, with the support of Moderna, leverage our platform to advance vaccines through pre-clinical development.
Researchers who join the collaborative model will have access to our platform and support from our research teams.
Partner with us to bring this global health initiative to life.